Jupiter Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jupiter Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.24M	Buy	592,654 +577,080	+3,705%	+$8.12M	0.04%	308
2025 Q4	$188K	Buy	+15,574	New	+$212K	﹤0.01%	401
2024 Q1	–	Sell	-1,060,900	Closed	-$15.6M	–	428
2023 Q4	$15.6M	Buy	1,060,900 +411,164	+63%	+$6.3M	0.15%	171
2023 Q3	$11.9M	Buy	+649,736	New	+$13.7M	0.13%	183

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jupiter Asset Management's AMLX Position: Q1 2026 in Review

Jupiter Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 3,705% in Q1 2026, buying an estimated $8.12M and bringing the position to 592,654 shares worth $8.24M. The position accounts for 0.04% of the portfolio, ranked #308.

Jupiter Asset Management first reported a position in AMLX in Q3 2023 and has held it in 4 quarters since. The position peaked at $15.6M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Jupiter Asset Management held 592,654 shares of Amylyx Pharmaceuticals worth $8.24M as of Q1 2026.
Jupiter Asset Management bought 577,080 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $8.12M.
Amylyx Pharmaceuticals made up 0.04% of Jupiter Asset Management's portfolio in Q1 2026, its #308 holding.
Jupiter Asset Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
Jupiter Asset Management's Amylyx Pharmaceuticals position peaked at $15.6M in Q4 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Jupiter Asset Management's 13F filing for Q1 2026, filed 12 May 2026.